Intervacc is trading 21.72% down at €0.04; the reason for the decline remains unconfirmed.
- The latest available company update concerns an EMA application for a longer duration of immunity for Strangvac.
- Q3 results are scheduled for November 12, but the upcoming report does not explain the move.
- Available coverage and the supplied mixed broad-market information do not establish a specific cause.